menu
    • menu
    [{"orgOrder":0,"company":"NurrOn Pharmaceuticals","sponsor":"Hanall Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"ATH-399A","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"NurrOn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"NurrOn Pharmaceuticals \/ HanAll Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"NurrOn Pharmaceuticals \/ HanAll Biopharma"},{"orgOrder":0,"company":"NurrOn Pharmaceuticals","sponsor":"Hanall Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ATH-399A","moa":"","graph1":null,"graph2":null,"graph3":"NurrOn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"NurrOn Pharmaceuticals \/ NurrOn Pharmaceuticals","highestDevelopmentStatusID":null,"companyTruncated":"NurrOn Pharmaceuticals \/ NurrOn Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by NurrOn Pharmaceuticals

    Menu

    NurrOn Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NurrOn Pharmaceuticals

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            NurrOn Pharmaceuticals

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATH-399A

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Hanall Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HanAll, Daewoong and NurrOn Complete First Human Parkinson’s Therapy Study

                            Details : HL192(ATH-399A) is a first-in-class small molecule that focuses on activating Nurr1, it is being investigating for treating Parkinson's Disease.

                            Brand Name : HL192

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 25, 2024

                            Lead Product(s) : ATH-399A

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Hanall Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NurrOn Pharmaceuticals

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            NurrOn Pharmaceuticals

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATH-399A

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Hanall Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals t...

                            Details : HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative dis...

                            Brand Name : ATH-399A

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 25, 2023

                            Lead Product(s) : ATH-399A

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Hanall Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth